Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
作者信息
Subbiah Vivek, Slopis John, Hong David S, Ketonen Leena M, Hamilton Jackson, McCutcheon Ian E, Kurzrock Razelle
机构信息
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
出版信息
J Clin Oncol. 2012 Feb 10;30(5):e64-8. doi: 10.1200/JCO.2011.38.2614. Epub 2011 Dec 27.
Abstract
摘要
相似文献
1
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
J Clin Oncol. 2012 Feb 10;30(5):e64-8. doi: 10.1200/JCO.2011.38.2614. Epub 2011 Dec 27.
2
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Oncologist. 2011;16 Suppl 2(Suppl 2):32-44. doi: 10.1634/theoncologist.2011-S2-32.
3
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Expert Rev Anticancer Ther. 2009 Mar;9(3):373-9. doi: 10.1586/14737140.9.3.373.
4
[Adverse effects of new oncologic therapies].
Praxis (Bern 1994). 2011 Jul 27;100(15):885-91; quiz 890. doi: 10.1024/1661-8157/a000609.
5
[Targeted therapies and their indications in solid neoplasias].
Rev Med Interne. 2009 May;30(5):416-24. doi: 10.1016/j.revmed.2008.12.022. Epub 2009 Mar 18.
6
Targeted therapy in advanced non-small-cell lung cancer.
Semin Respir Crit Care Med. 2008 Jun;29(3):291-301. doi: 10.1055/s-2008-1076749.
7
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
Clin Genitourin Cancer. 2013 Mar;11(1):1-4. doi: 10.1016/j.clgc.2012.11.006. Epub 2012 Dec 29.
8
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Clin Genitourin Cancer. 2014 Aug;12(4):262-9. doi: 10.1016/j.clgc.2014.03.002. Epub 2014 Mar 14.
9
Promising systemic therapy for renal cell carcinoma.
Curr Treat Options Oncol. 2005 Sep;6(5):357-65. doi: 10.1007/s11864-005-0039-5.
10
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24.
引用本文的文献
1
Management Strategies of Neurofibromatosis Type 2 in Pediatric Patients : Challenges and Emerging Therapies.
J Korean Neurosurg Soc. 2025 May;68(3):278-285. doi: 10.3340/jkns.2024.0237. Epub 2025 Feb 24.
2
Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review.
Cancers (Basel). 2025 Feb 4;17(3):519. doi: 10.3390/cancers17030519.
3
Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses.
Med. 2024 Jul 12;5(7):689-717. doi: 10.1016/j.medj.2024.04.008. Epub 2024 May 14.
4
Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1.
J Immunother Precis Oncol. 2024 May 2;7(2):122-125. doi: 10.36401/JIPO-23-32. eCollection 2024 May.
5
Development of Novel Bioluminescent Biosensors Monitoring the Conformation and Activity of the Merlin Tumour Suppressor.
Int J Mol Sci. 2024 Jan 26;25(3):1527. doi: 10.3390/ijms25031527.
6
Long-term outcomes of stereotactic radiosurgery for intracranial schwannoma in neurofibromatosis type 2: a genetic analysis perspective.
J Neurooncol. 2024 Jan;166(1):185-194. doi: 10.1007/s11060-023-04530-0. Epub 2023 Dec 27.
7
Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Int J Mol Sci. 2021 May 29;22(11):5850. doi: 10.3390/ijms22115850.
8
Therapy of Sporadic and NF2-Related Vestibular Schwannoma.
Cancers (Basel). 2020 Mar 31;12(4):835. doi: 10.3390/cancers12040835.
9
The paradox of cancer genes in non-malignant conditions: implications for precision medicine.
Genome Med. 2020 Feb 17;12(1):16. doi: 10.1186/s13073-020-0714-y.
10
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2.
Nat Commun. 2019 Dec 17;10(1):5758. doi: 10.1038/s41467-019-13640-1.
本文引用的文献
1
Medical therapies for meningiomas.
J Neurooncol. 2010 Sep;99(3):365-78. doi: 10.1007/s11060-010-0349-8. Epub 2010 Sep 4.
2
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Otol Neurotol. 2010 Sep;31(7):1135-43. doi: 10.1097/MAO.0b013e3181eb328a.
3
Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Neuro Oncol. 2010 Jan;12(1):14-8. doi: 10.1093/neuonc/nop010. Epub 2009 Oct 20.
4
The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Rev Neurol Dis. 2009 Summer;6(3):E81-6.
5
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Clin Cancer Res. 2009 Aug 15;15(16):5032-5039. doi: 10.1158/1078-0432.CCR-08-3011. Epub 2009 Aug 11.
6
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
N Engl J Med. 2009 Jul 23;361(4):358-67. doi: 10.1056/NEJMoa0902579. Epub 2009 Jul 8.
7
Neurofibromatosis type 2 (NF2): a clinical and molecular review.
Orphanet J Rare Dis. 2009 Jun 19;4:16. doi: 10.1186/1750-1172-4-16.
8
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
Cancer Chemother Pharmacol. 2010 Jan;65(2):235-41. doi: 10.1007/s00280-009-1027-4.
9
Neurofibromatosis type 2.
Lancet. 2009 Jun 6;373(9679):1974-86. doi: 10.1016/S0140-6736(09)60259-2. Epub 2009 May 22.
10
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
Nat Clin Pract Oncol. 2008 Aug;5(8):487-91. doi: 10.1038/ncponc1157. Epub 2008 Jun 17.
Zotero 插件